ProPhase Labs (PRPH) announced that its study, “Assessing Risk of Progression in Barrett’s Esophagus Using a Mass-Spectrometry-Based Proteomic Panel,” has been published online in Clinical and Translational Gastroenterology, the official journal of the American College of Gastroenterology, ACG. The publication presents full clinical validation data supporting BE-Smart, an 8-protein, mass-spectrometry-based proteomic assay developed for risk stratification of patients with Barrett’s Esophagus. Conducted in collaboration with the Mayo Clinic, the study demonstrates that BE-Smart provides a highly accurate, molecularly driven method for identifying BE patients most likely to progress to high-grade dysplasia or esophageal adenocarcinoma. These findings position BE-Smart as a next-generation molecular screening tool ready for broad clinical adoption and reimbursement discussions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRPH:
- ProPhase Labs engages RedChip to lead investor relations efforts
- ProPhase Labs announces study validating BE-Smart cancer test
- ProPhase Labs files to sell 226.31M shares of common stock for holders
- ProPhase Labs Signs Sales Agreement with WestPark Capital
- ProPhase announces three COVID-19 testing companies filed for reorganization